Abstract
Purpose
Symptomatic adverse events (AEs) are monitored by clinicians as part of all US-based clinical trials in cancer via the U.S. National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE) for the purposes of ensuring patient safety. Recently, there has been a charge toward capturing the patient perspective for those AEs amenable to patient self-reporting via patient-reported outcomes (PRO). The aim of this review was to summarize the empirically reported association between analogous CTCAE and PRO ratings.
Methods
A systematic literature search was conducted using PubMed, EMBASE, Web of Science, and Cochrane databases through July 2015. From a total of 5658 articles retrieved, 28 studies met the inclusion criteria.
Results
Across studies, patients were of mixed cancer types, including anal, breast, cervical, chronic myeloid leukemia, endometrial, hematological, lung, ovarian, pelvic, pharyngeal, prostate, and rectal. Given this mixture, the AEs captured were variable, with many common across studies (e.g., dyspnea, fatigue, nausea, neuropathy, pain, vomiting), as well as several that were disease-specific (e.g., erectile dysfunction, hemoptysis). Overall, the quantified association between CTCAE and PRO ratings fell in the fair to moderate range and had a large variation across the majority of studies (n = 21).
Conclusions
The range of measures used and symptoms captured varied greatly across the reviewed studies. Regardless of concordance metric employed, reported agreement between CTCAE and PRO ratings was moderate at best. To assist with reconciliation and interpretation of these differences toward ultimately improving patient care, an important next step is to explore approaches to integrate PROs with clinician reporting of AEs.
Similar content being viewed by others
Notes
Questions 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 16, 17, 18, 19, 20, and 26 from the Downs and Black Study Quality Checklist were used to assess quality.
References
Basch E (2010) The missing voice of patients in drug-safety reporting. N Engl J Med 362:865–869
Basch E (2014) New frontiers in patient-reported outcomes: adverse event reporting, comparative effectiveness, and quality assessment. Annu Rev Med 65:307–317
Vyzula RRS (1996) Lung cancer in patients with HIV-infection. Lung Cancer 15:325–339
Basch E, Reeve BB, Mitchell SA, et al. (2014) Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 106:dju244
Basch E (2012) Beyond the FDA PRO guidance: steps toward integrating meaningful patient-reported outcomes into regulatory trials and US drug labels. Value Health 15:401–403
Trotti A, Colevas AD, Setser A, Basch E (2007) Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol 25:5121–5127
US Department of Health and Human Services (2009) Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. Accessed 5 Jan 2016
Hay JL, Atkinson TM, Reeve BB, et al. (2014) Cognitive interviewing of the US National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Qual Life Res 23:257–269
Dueck AC, Mendoza TR, Mitchell SA, et al. (2015) Validity and reliability of the U.S. National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol 1:1051–1059
Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 52:377–384
Mandala M, Cremonesi M, Rocca A, et al. (2005) Midazolam for acute emesis refractory to dexamethasone and granisetron after highly emetogenic chemotherapy: a phase II study. Support Care Cancer 13:375–380
Alberti P, Rossi E, Cornblath DR, et al. (2014) Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann Oncol 25:257–264
Brabo EP, Paschoal ME, Biasoli I, et al. (2006) Brazilian version of the QLQ-LC13 lung cancer module of the European Organization for Research and Treatment of Cancer: preliminary reliability and validity report. Qual Life Res 15:1519–1524
Christodoulou M, McCloskey P, Stones N, et al. (2014) Investigation of a patient reported outcome tool to assess radiotherapy-related toxicity prospectively in patients with lung cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol 112:244–249
Di Maio M, Gallo C, Leighl NB, et al. (2015) Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 33:910–915
Fromme EK, Eilers KM, Mori M, Hsieh YC, Beer TM (2004) How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patient-reported symptoms from the quality-of-life questionnaire C30. J Clin Oncol 22:3485–3490
Greimel ER, Bjelic-Radisic V, Pfisterer J, et al. (2011) Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trials. Support Care Cancer 19:1421–1427
Jensen K, Lambertsen K, Torkov P, et al. (2007) Patient assessed symptoms are poor predictors of objective findings. Results from a cross sectional study in patients treated with radiotherapy for pharyngeal cancer. Acta Oncol 46:1159–1168
Kirchheiner K, Nout R, Lindegaard J, et al. (2012) Do clinicians and patients agree regarding symptoms? A comparison after definitive radiochemotherapy in 223 uterine cervical cancer patients. Strahlenther Onkol: Organ der Deutschen Rontgengesellschaft [et al] 188:933–939
Quinten C, Maringwa J, Gotay CC, et al. (2011) Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. J Natl Cancer Inst 103:1851–1858
Cella D, Huang H, Homesley HD, et al. (2010a) Patient-reported peripheral neuropathy of doxorubicin and cisplatin with and without paclitaxel in the treatment of advanced endometrial cancer: results from GOG 184. Gynecol Oncol 119:538–542
Hirsh V, Okamoto I, Hon JK, et al. (2014) Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer. J Thoracic Oncol Off Publ int Assoc Study Lung Cancer 9:83–90
Shimozuma K, Ohashi Y, Takeuchi A, et al. (2009) Feasibility and validity of the patient neurotoxicity questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Support Care Cancer 17:1483–1491
Atherton PJ, Burger KN, Loprinzi CL, et al. (2012) Using the Skindex-16 and common terminology criteria for adverse events to assess rash symptoms: results of a pooled-analysis (N0993). Support Care Cancer 20:1729–1735
Neben-Wittich MA, Atherton PJ, Schwartz DJ, et al. (2011) Comparison of provider-assessed and patient-reported outcome measures of acute skin toxicity during a phase III trial of mometasone cream versus placebo during breast radiotherapy: the North Central Cancer Treatment Group (N06C4). Int J Radiat Oncol Biol Phys 81:397–402
Basch E, Jia X, Heller G, et al. (2009) Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst 101:1624–1632
Efficace F, Rosti G, Aaronson N, et al. (2014) Patient- versus physician-reporting of symptoms and health status in chronic myeloid leukemia. Haematologica 99:788–793
Flores LT, Bennett AV, Law EB, et al. (2012) Patient-reported outcomes vs. clinician symptom reporting during chemoradiation for rectal cancer. Gastrointest Cancer Res GCR 5:119–124
Tom A, Bennett A, Rothenstein D, et al. (2013) Prevalence of patient-reported gastrointestinal symptoms and concordance with clinician toxicity assessments in radiation therapy for anal cancer. Int J Radiat Oncol Biol Phys 87:S570–S571
Basch E, Iasonos A, McDonough T, et al. (2006) Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol 7:903–909
Cirillo M, Venturini M, Ciccarelli L, et al. (2009) Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient’s self-reported questionnaire. Ann Oncol 20:1929–1935
Gravis G, Marino P, Joly F, et al. (2014) Patients’ self-assessment versus investigators’ evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15). Eur J Cancer 50:953–962
Cella D, Pulliam J, Fuchs H, et al. (2003) Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. Cancer 98:406–412
Steinsvik EA, Fossa SD, Axcrona K, et al. (2010) Do perceptions of adverse events differ between patients and physicians? Findings from a randomized, controlled trial of radical treatment for prostate cancer. J Urol 184:525–531
Franklin HR, Simonetti GP, Dubbelman AC, et al. (1994) Toxicity grading systems. A comparison between the WHO scoring system and the Common Toxicity Criteria when used for nausea and vomiting. Ann Oncol 5:113–117
Cella D, Riley W, Stone A, et al. (2010b) The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008. J Clin Epidemiol 63:1179–1194
Bennett BK, Park SB, Lin CS, et al. (2012) Impact of oxaliplatin-induced neuropathy: a patient perspective. Support Care Cancer 20:2959–2967
Tang B, Giuliani M, Le LW, et al. (2013) Capturing acute toxicity data during lung radiotherapy by using a patient-reported assessment tool. Clin Lung Cancer 14:108–112
Gotay CC, Kawamoto CT, Bottomley A, Efficace F (2008) The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol 26:1355–1363
Atkinson TM, Li Y, Coffey CW, et al. (2012) Reliability of adverse symptom event reporting by clinicians. Qual Life Res 21:1159–1164
Park JH, Kim YS, Park J, et al. (2014) Incidence and dose-volume analysis of acute bladder toxicity following pelvic radiotherapy. Tumori 100:195–200
Acknowledgments
This project was supported by a National Institutes of Health Research Training Grant (T32 CA009461-25), as well as a National Institutes of Health Support Grant (P30 CA08748-48), which provides partial support for the Behavioral Research Methods Core Facility used in conducting this investigation. The authors wish to thank Jan-Samuel Wagner for his early contributions to the project, as well as Dr. Jamie Ostroff for her support of this work. A portion of these results were presented at the 2013 Conference of the International Society for Quality of Life Research in Miami, FL.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Rights and permissions
About this article
Cite this article
Atkinson, T.M., Ryan, S.J., Bennett, A.V. et al. The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Support Care Cancer 24, 3669–3676 (2016). https://doi.org/10.1007/s00520-016-3297-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-016-3297-9